• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

ChromoTek PD-1 VHH, recombinant binding protein for 2x Cys conjugation

Alpaca anti-PD-1 VHH, purified recombinant binding protein. Suitable for for cysteine conjugation with thiol-reactive reagents, e.g. maleimides. Note: unconjugated VHHs are not suited for usage without prior labeling, since they contain reactive Cysteines. Shipment and storage buffers contain TCEP to keep Cysteins reduced.

Host/Type

Alpaca VHH

Reactivity

Human

Applications

Conjugation

Conjugate

Unconjugated

Cat No : pd1Cys2

Synonyms

PD-1-Nanobody, PD-1-Single domain antibody (sdAb), CD279, hPD-1, PD1 PD-1, programmed cell death protein 1

Validation Data Gallery

Product Information

Alpaca anti-PD-1 VHH, purified recombinant binding protein. Suitable for for cysteine conjugation with thiol-reactive reagents, e.g. maleimides. Note: unconjugated VHHs are not suited for usage without prior labeling, since they contain reactive Cysteines. Shipment and storage buffers contain TCEP to keep Cysteins reduced.

ApplicationsConjugation
ReactivityHuman
ConjugateUnconjugated
Type Nanobody
ClassRecombinant
HostAlpaca
AffinityPicomolar range, below the assay limit (biolayer interferometry)
Molecular Weight13.874 kDa
FormLiquid
RRID/
Storage Buffer10 mM HEPES, 500 mM NaCl, pH 7.0, 1 mM TCEP, 0.09% sodium azide
Storage ConditionStore at -20°C
BackgroundProgrammed cell death 1 (PD-1, also known as CD279) is an immunoinhibitory receptor that belongs to the CD28/CTLA-4 subfamily of the Ig superfamily. It is a 288 amino acid (aa) type I transmembrane protein composed of one Ig superfamily domain, a stalk, a transmembrane domain, and an intracellular domain containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) as well as an immunoreceptor tyrosine-based switch motif (ITSM) (PMID: 18173375). PD-1 is expressed during thymic development and is induced in a variety of hematopoietic cells in the periphery by antigen receptor signaling and cytokines (PMID: 20636820). Engagement of PD-1 by its ligands PD-L1 or PD-L2 transduces a signal that inhibits T-cell proliferation, cytokine production, and cytolytic function (PMID: 19426218). It is critical for the regulation of T cell function during immunity and tolerance. Blockade of PD-1 can overcome immune resistance and also has been shown to have antitumor activity (PMID: 22658127; 23169436). It has been reported that PD-1 is heavily glycosylated and migrates with an apparent molecular mass of 47-55 kDa on SDS-PAGE, which is larger than its predicted mass of 32 kDa (PMID: 8671665; 17640856; 17003438).

Documentation

SDS
SDS-Immuno-Oncology VHHs